Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7

Blood. 2009 Mar 19;113(12):2867-8. doi: 10.1182/blood-2008-12-195693.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antimetabolites, Antineoplastic / pharmacology
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Azacitidine / pharmacology
  • Azacitidine / therapeutic use*
  • Bone Marrow Cells / ultrastructure
  • Calcitonin / genetics
  • Chromosomes, Human, Pair 7*
  • Clone Cells / ultrastructure
  • Combined Modality Therapy
  • CpG Islands
  • DNA Methylation / drug effects
  • Genes, ras
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Infant
  • Leukemia, Myelomonocytic, Juvenile / drug therapy*
  • Leukemia, Myelomonocytic, Juvenile / genetics
  • Leukemia, Myelomonocytic, Juvenile / surgery
  • Male
  • Monosomy*
  • Neoplasm Proteins / genetics
  • Point Mutation
  • Promoter Regions, Genetic
  • Protein Precursors / genetics
  • Remission Induction

Substances

  • Antimetabolites, Antineoplastic
  • Neoplasm Proteins
  • Protein Precursors
  • Calcitonin
  • Azacitidine